APTO 253

Drug Profile

APTO 253

Alternative Names: APTO-253; LOR-253; LOR-253 HCl; LT-253

Latest Information Update: 02 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lorus Therapeutics
  • Developer Aptose Biosciences
  • Class Antineoplastics; Imidazoles; Indoles; Phenanthrolines; Small molecules
  • Mechanism of Action Apoptosis stimulants; GKLF protein stimulants; Proto oncogene protein c-myc inhibitors; Transcription factor MTF-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 23 Jan 2017 Suspended - Phase-I for Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV)
  • 23 Jan 2017 Suspended - Phase-I for Haematological malignancies (Second-line therapy or greater) in USA (IV)
  • 23 Jan 2017 Suspended - Phase-I for Myelodysplastic syndromes (Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top